Sheraton Tamarron Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2001
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Cancer Intervention (C6)
Organizer(s) George F. Vande Woude, Sara A. Courtneidge and Frank McCormick
February 28—March 5, 2001
Sheraton Tamarron Resort • Durango, Colorado USA
Abstract Deadline: Oct 27, 2000
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Dec 28, 2000
Sponsored by Abbott Laboratories
Summary of Meeting:
After decades of research into the vast numbers of factors that contribute to cancer, we are beginning to exploit this knowledge in developing new prevention and cancer treatment strategies. There are now hundreds of new therapies and drugs being evaluated and in the next decade we expect to see remarkable improvements in the way we deal with cancer, from drugs that specifically target the products of cancer genes, to novel compounds that reduce cancer risk. Small molecule inhibitors are in clinical trials that target kinases, as are engineered viral vectors that target tumors deficient in tumor suppressor genes, immunotoxins and cancer “vaccines” that target tumor cells and therapeutics that reduce risk in individuals with inherited predispositions. No one is quite sure how well they will work and with current procedures there are enormous obstacles and delays in evaluating their potential. In addition, there is still a need to improve on the use of chemotherapeutic drugs and the application of existing therapies, when combined with advancements in diagnostic and imaging technologies. The purpose of this conference will be to explore progress on these fronts by inviting the leading investigators in cancer intervention strategies.
View Scholarships/Awards
After decades of research into the vast numbers of factors that contribute to cancer, we are beginning to exploit this knowledge in developing new prevention and cancer treatment strategies. There are now hundreds of new therapies and drugs being evaluated and in the next decade we expect to see remarkable improvements in the way we deal with cancer, from drugs that specifically target the products of cancer genes, to novel compounds that reduce cancer risk. Small molecule inhibitors are in clinical trials that target kinases, as are engineered viral vectors that target tumors deficient in tumor suppressor genes, immunotoxins and cancer “vaccines” that target tumor cells and therapeutics that reduce risk in individuals with inherited predispositions. No one is quite sure how well they will work and with current procedures there are enormous obstacles and delays in evaluating their potential. In addition, there is still a need to improve on the use of chemotherapeutic drugs and the application of existing therapies, when combined with advancements in diagnostic and imaging technologies. The purpose of this conference will be to explore progress on these fronts by inviting the leading investigators in cancer intervention strategies.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
WEDNESDAY, FEBRUARY 28
THURSDAY, MARCH 1
FRIDAY, MARCH 2
SATURDAY, MARCH 3
SUNDAY, MARCH 4
MONDAY, MARCH 5
Conference Program Print | View meeting in 12 hr (am/pm) time
WEDNESDAY, FEBRUARY 28
14:00—19:00
Registration
Alcove
19:15—20:15
Welcome
Windom Peak
20:15—20:30
Orientation
Silverton
20:30—21:30
Keynote Address
Silverton
07:00—08:00
Breakfast
Windom Peak
08:00—11:00
Novel Targets/Novel Therapeutics I
Silverton
Hamilton Jordan,
Hamilton Jordan, USA
Keynote Address:
Keynote Address:
Brian J. Druker,
Oregon Health & Science University Cancer Institute, USA
STI571: A Tyrosine Kinase Inhibitor for the Treatment of CML – Validating the Promise of Molecularly Targeted Therapy
STI571: A Tyrosine Kinase Inhibitor for the Treatment of CML – Validating the Promise of Molecularly Targeted Therapy
Dennis J. Slamon,
University of California, Los Angeles, USA
Use of the Anti HER-2/neu Antibody Herceptin in the Treatment of Human Breast Cancer: Biologic Rational and Clinical Results
Use of the Anti HER-2/neu Antibody Herceptin in the Treatment of Human Breast Cancer: Biologic Rational and Clinical Results
*
John Mendelsohn,
University of Texas, USA
Inhibitition of EGF Receptors as Anticancer Therapy
Inhibitition of EGF Receptors as Anticancer Therapy
09:20—09:40
Coffee Break
Windom Peak
11:00—13:00
Poster Setup
Innisbrook/Animas
16:00—18:00
POSTER SESSION 1: Novel Targets/Novel Therapeutics
Innisbrook/Animas
17:00—18:00
Social Hour
Innisbrook Foyer
20:00—21:00
Coffee Available
Windom Peak
20:00—22:00
Novel Targets/Novel Therapeutics II
Silverton
Edward A. Sausville,
University of Maryland, USA
Optimizing Cytotoxic and Cytostatic Endpoints: How to?
Optimizing Cytotoxic and Cytostatic Endpoints: How to?
Julian H. Downward,
Cancer Research UK, UK
Oncogene Regulation of Cell Death
Oncogene Regulation of Cell Death
07:00—08:00
Breakfast
Windom Peak
08:00—11:00
Profiling of Cancers and Treatments
Silverton
*
Robert L. Strausberg,
National Institutes of Health, USA
The Cancer Genome Anatomy Project: Reading the Molecular Signatures of Cancer
The Cancer Genome Anatomy Project: Reading the Molecular Signatures of Cancer
Donna G. Albertson,
University of California, San Francisco, USA
Measurement of DNA Sequence Copy Number Using Comparative Genomic Hybridization to Microarrays
Measurement of DNA Sequence Copy Number Using Comparative Genomic Hybridization to Microarrays
Dai Fukumura,
Massachusetts General Hospital, USA
In vivo Imaging of Gene Expression and Physiological Function in Tumors
In vivo Imaging of Gene Expression and Physiological Function in Tumors
09:20—09:40
Coffee Break
Windom Peak
11:00—13:00
Poster Setup
Innisbrook/Animas
16:00—18:00
POSTER SESSION 2 & 3: Profiling of Cancers and Treatments/Cancer Prevention/Preclinical Models/New Approaches/Invasion/Metastasis/Angiogenesis/Biological Therapy
Innisbrook/Animas
17:00—18:00
Social Hour
Innisbrook Foyer
20:00—21:00
Coffee Available
Windom Peak
20:00—22:00
Cancer Prevention
Silverton
Leslie Ford,
National Cancer Institute, National Institutes of Health, USA
Study of Tamoxifen and Raloxifene (STAR) - An Intervention to Reduce Breast Cancer Risk
Study of Tamoxifen and Raloxifene (STAR) - An Intervention to Reduce Breast Cancer Risk
*
Alice S. Whittemore,
Stanford University, USA
Genetic Predisposition to Prostate Cancer: Possible Explanations for Ethnic Differences in Risk
Genetic Predisposition to Prostate Cancer: Possible Explanations for Ethnic Differences in Risk
07:00—08:00
Breakfast
Windom Peak
08:00—11:00
Preclinical Models
Silverton
*
Douglas Hanahan,
ISREC, Switzerland
Prototyping Multistage Carcinogenesis in Mice: Elaborating Mechanisms and Assessing Strategies for Prevention and Therapy
Prototyping Multistage Carcinogenesis in Mice: Elaborating Mechanisms and Assessing Strategies for Prevention and Therapy
Tyler Jacks,
Massachusetts Institute of Technology, USA
Modeling Human Lung Cancer in Mice: Similarities and Shortcomings
Modeling Human Lung Cancer in Mice: Similarities and Shortcomings
Ronald A. DePinho,
University of Texas MD Anderson Cancer Center, USA
Telomerase and Tumor Therapy
Telomerase and Tumor Therapy
Martin Oft,
ARMO BioSciences, USA
Genetic Control of Tumor Susceptibility in the Mouse
Genetic Control of Tumor Susceptibility in the Mouse
09:20—09:40
Coffee Break
Windom Peak
11:00—13:00
Poster Setup
Innisbrook/Animas
16:00—18:00
POSTER VIEWING ALL SESSIONS
Innisbrook/Animas
17:00—18:00
Social Hour
Innisbrook Foyer
20:00—21:00
Coffee Available
Windom Peak
20:00—22:00
New Approaches
Silverton
Robert E. Wittes,
Memorial Sloan-Kettering Cancer Center, USA
Keynote Speaker: Molecular Targeting and Clinical Oncology
Keynote Speaker: Molecular Targeting and Clinical Oncology
Frank McCormick,
University of California, San Francisco, USA
Oncolytic Viruses
Oncolytic Viruses
William G. Kaelin, Jr.,
Dana-Farber Cancer Institute, USA
Anticancer Strategies Based on Functional Inactivation of the Retinoblastoma Protein
Anticancer Strategies Based on Functional Inactivation of the Retinoblastoma Protein
07:00—08:00
Breakfast
Windom Peak
08:00—11:00
Invasion/Metastasis/Angiogenesis
Silverton
Ann F. Chambers,
London Regional Cancer Centre, Canada
Metastasis: Mechanisms and Therapeutic Targets
Metastasis: Mechanisms and Therapeutic Targets
Charles Streuli,
University of Manchester, UK
Adhesion and Apoptosis: Novel Targets for Intervention
Adhesion and Apoptosis: Novel Targets for Intervention
*
Zena Werb,
University of California, San Francisco, USA
The Role of Matrix Metalloproteinases in Neoplasia
The Role of Matrix Metalloproteinases in Neoplasia
09:20—09:40
Coffee Break
Windom Peak
16:00—17:00
Coffee Available
Windom Peak
15:30—17:30
Biological Therapy
Silverton
Douglas Lowy,
NCI, National Institutes of Health, USA
Viral Vaccines
Viral Vaccines
*
James P. Allison,
University of Texas MD Anderson Cancer Center, USA
Augmenting Anti-Tumor Immune Responses by Manipulation of T Cell Regulatory Signals
Augmenting Anti-Tumor Immune Responses by Manipulation of T Cell Regulatory Signals
19:00—20:00
Social Hour
Windom Peak
20:00—22:00
Banquet
Silverton
21:00—00:00
Entertainment
Silverton
Departure
*Session Chair †Invited, not yet responded.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
